TSE:CRON Cronos Group Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cronos Group Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$6.79 -0.05 (-0.73 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's RangeC$6.68Now: C$6.79▼C$6.8950-Day RangeC$6.76MA: C$7.17▼C$7.7852-Week RangeC$5.82Now: C$6.79▼C$13.87Volume512,485 shsAverage Volume998,201 shsMarket CapitalizationC$2.38 billionP/E Ratio3.48Dividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsHeadlinesOptions ChainSocial Media Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.Read More Beat the Market (BTM) Rank™ 3.1 Analyst's Opinion Consensus RatingCronos Group has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of C$9.39, Cronos Group has a forecasted upside of 38.3% from its current price of C$6.79.Amount of Analyst CoverageCronos Group has only been the subject of 1 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesCronos Group has received 59 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCronos Group has received 77 “underperform” votes. (Add your “underperform” vote.)Community SentimentCronos Group has received 56.62% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote “Outperform” if you believe CRON will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCronos Group does not currently pay a dividend.Dividend GrowthCronos Group does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cronos Group insiders have not sold or bought any company stock. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cronos Group is 3.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 18.38.Price to Earnings Ratio vs. SectorThe P/E ratio of Cronos Group is 3.48, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.59.Price to Earnings Growth RatioDue to a projected decrease in earnings for Cronos Group, their PEG ratio cannot be calculated.Price to Book Value per Share RatioCronos Group has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.31 out of 5 stars Industry, Sector and Symbol Stock Exchange TSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:CRON Previous Symbol CUSIPN/A CIKN/A Webwww.thecronosgroup.com Phone416-504-0004Debt Debt-to-Equity Ratio0.61 Current Ratio5.96 Quick Ratio5.68Price-To-Earnings Trailing P/E Ratio3.48 Forward P/E RatioN/A P/E Growth-0.82 Sales & Book Value Annual SalesC$31.41 million Price / Sales75.64 Cash FlowC$3.73 per share Price / Cash Flow1.82 Book ValueC$4.76 per share Price / Book1.43Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees291 Outstanding Shares349,886,000Market CapC$2.38 billion Next Earnings DateN/A OptionableOptionable C$6.79 -0.05 (-0.73 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CRON News and Ratings via Email Sign-up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter. Cronos Group (TSE:CRON) Frequently Asked Questions How has Cronos Group's stock been impacted by COVID-19? Cronos Group's stock was trading at C$7.45 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CRON stock has decreased by 8.9% and is now trading at C$6.79. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Cronos Group? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cronos Group. What price target have analysts set for CRON? 5 brokerages have issued 12 month price objectives for Cronos Group's stock. Their forecasts range from C$5.60 to C$17.00. On average, they expect Cronos Group's stock price to reach C$9.39 in the next year. This suggests a possible upside of 38.3% from the stock's current price. View analysts' price targets for Cronos Group. Who are some of Cronos Group's key competitors? Some companies that are related to Cronos Group include Vir Biotechnology (VIR), Repare Therapeutics (BLI), MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR), MorphoSys (MOR), MorphoSys (MOR), BTG (BTG), Abcam (ABC), Kodiak Sciences (KOD), Genus (GNS), Trillium Therapeutics (TRIL), Viela Bio (VIE), Concordia International (CXR), NGM Biopharmaceuticals (NGM), PureTech Health (PRTC) and Aptose Biosciences (APS). View all competitors. What other stocks do shareholders of Cronos Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cronos Group investors own include Aurora Cannabis (ACB), Canopy Growth (CGC), Aurora Cannabis (ACB), Canopy Growth (WEED), NVIDIA (NVDA), Aphria (APHA), Advanced Micro Devices (AMD), Netflix (NFLX), Walt Disney (DIS) and Tesla (TSLA). Who are Cronos Group's key executives? Cronos Group's management team includes the following people: Mr. Michael Gorenstein, Chairman, Pres & CEO (Age 31)Mr. David Hsu, Chief Operating OfficerMs. Xiuming Shum, Gen. Counsel & Corp. Sec.Mr. Jeffrey Jacobson, Head of Sales & Bus. Devel.Mr. William Hilson, Chief Commercial Officer What is Cronos Group's stock symbol? Cronos Group trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CRON." How do I buy shares of Cronos Group? Shares of CRON and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Cronos Group's stock price today? One share of CRON stock can currently be purchased for approximately C$6.79. How big of a company is Cronos Group? Cronos Group has a market capitalization of C$2.38 billion and generates C$31.41 million in revenue each year. Cronos Group employs 291 workers across the globe. What is Cronos Group's official website? The official website for Cronos Group is www.thecronosgroup.com. How can I contact Cronos Group? The company can be reached via phone at 416-504-0004. This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
